Literature DB >> 28918734

The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders.

David J Castle1, Cherrie A Galletly2, Frances Dark3, Verity Humberstone4, Vera A Morgan5, Eóin Killackey6, Jayashri Kulkarni7, Patrick McGorry8, Olav Nielssen9, Nga T Tran10, Assen Jablensky5.   

Abstract

INTRODUCTION: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) clinical practice guidelines for the management of schizophrenia and related disorders provide evidence-based recommendations for optimising treatment and prognosis. This update to the 2005 RANZCP guidelines has a greater emphasis on psychosocial treatments, physical health comorbidities and vocational rehabilitation. Main recommendations: The guidelines advise a clinical staging approach and deliver specific recommendations for:•comprehensive treatment using second generation antipsychotic agents continuously for 2-5 years;•early treatment of comorbid substance use;•community treatment after initial contact, during crises and after discharge from hospital;•physical health monitoring and management of comorbidities, particularly metabolic health;•interventions to optimise recovery of social function and return to study or work; and•management of schizophrenia in specific populations and circumstances. Changes in management as a result of the guidelines: The guidelines provide benchmarks against which the performance of services and clinical teams can be assessed. Measuring treatment response and clinical outcome is essential. General practitioners have an important role, particularly in monitoring and reducing the high cardiovascular risk in this population. Clinical services focusing on early detection, treatment and recovery need continuous funding to be proactive in implementing the guidelines and closing the gap between what is possible and what actually occurs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28918734     DOI: 10.5694/mja16.01159

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  4 in total

1.  DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.

Authors:  Charanraj Goud Alladi; Bruno Etain; Frank Bellivier; Cynthia Marie-Claire
Journal:  Int J Mol Sci       Date:  2018-10-04       Impact factor: 5.923

2.  Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.

Authors:  Kayo Ichihashi; Hikaru Hori; Naomi Hasegawa; Yuka Yasuda; Tomoya Yamamoto; Takashi Tsuboi; Kunihiro Iwamoto; Taishiro Kishimoto; Tadasu Horai; Hiroki Yamada; Nobuhiro Sugiyama; Toshinori Nakamura; Naohisa Tsujino; Kiyotaka Nemoto; Satoru Oishi; Masahide Usami; Eiichi Katsumoto; Hidenaga Yamamori; Hiroaki Tomita; Taro Suwa; Ryuji Furihata; Takahiko Inagaki; Junichi Fujita; Toshiaki Onitsuka; Kenichiro Miura; Junya Matsumoto; Kazutaka Ohi; Yuki Matsui; Yoshikazu Takaesu; Naoki Hashimoto; Junichi Iga; Kazuyoshi Ogasawara; Hisashi Yamada; Koichiro Watanabe; Ken Inada; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2020-06-30

3.  Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study.

Authors:  Corrado Barbui; Federico Bertolini; Francesco Bartoli; Carmela Calandra; Camilla Callegari; Giuseppe Carrà; Armando D'Agostino; Claudio Lucii; Giovanni Martinotti; Daniele Mastromo; Daniele Moretti; Emiliano Monzani; Matteo Porcellana; Davide Prestia; Giovanni Ostuzzi
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-22

4.  Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life.

Authors:  Ilaria Cuomo; Georgios D Kotzalidis; Simone de Persis; Daria Piacentino; Filippo Perrini; Emanuela Amici; Sergio De Filippis
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-21       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.